Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Research Impact Video
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health and Artificial Intelligence
      • Heart Health
      • Healthy Aging and Mobility
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
      • Learning and Development
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Indigenous Health Research Unit
      • VCH-VCHRI AI Hub
      • Communications and Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Indigenous Research
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. New prostate cancer tracer could revolutionize diagnosis of the disease

New prostate cancer tracer could revolutionize diagnosis of the disease

Stories Mar 31, 2017 4 minutes

Tracer could be more accurate in detection–and also lead to more successful treatment.

Dr. Philip Cohen, a Research Scientist with Vancouver Coastal Health Research Institute (VCHRI), has spent 35 years studying how to track and treat cancer using nuclear medicine—a medical specialty that uses radioactive substances in the diagnosis and treatment of disease. 

As a clinical professor of radiology at the University of British Columbia, Dr. Cohen has seen trial after trial fail to significantly improve detection and treatment options. But he is very excited about a new tracer he’s testing for prostate cancer. 

“I think the word breakthrough gets overused—but this is the closest to a breakthrough I’ve seen in my career.” Dr. Cohen says a new compound he’s investigating not only promises to be more accurate in detecting prostate cancer at an early stage, but could also be a more effective way of treating the disease. 

99mTc-MIP-1404 is a radiotracer that binds to a protein called PSMA (prostate-specific membrane antigen) commonly found in prostate cancer. This new compound acts as a homing molecule that travels through the body, finding PSMA in cells and binding to it. It then “lights up” on a scan, indicating where prostate cancer is located and how much of it there is. 

Currently, prostate cancer is diagnosed with a Prostate Specific Antigen (PSA) test, followed by an ultrasound and biopsy to confirm malignancy. Patients are then offered surgery, radiotherapy or a watch-and-wait approach. Prostate cancer is the most diagnosed cancer for men and kills about 4,000 Canadian men each year. 

“This new tracer promises to be far more accurate, at a much earlier stage, allowing us to make better decisions about treatment options.  Not only can it find prostate cancer in the prostate gland, it can seek it out anywhere in the body.”

That ability to seek out and find prostate cancer outside the gland—at a very early stage when bone scans and ultrasounds might not pick it up—has huge implications. If the cancer is found in the lymph nodes and bones (common sites for spread), the decision to surgically remove the prostate gland may change. On the other hand, if there is accurate information of no spread, patients and doctors can have more assurance that active surveillance is appropriate and opt to hold off on surgery and its possible complications.

Dr. Cohen’s study focuses on prostate cancer in the gland itself. Patients with prostate cancer who have chosen to have surgery to remove the gland will be scanned at Lion’s Gate Hospital after an injection of the new tracer compound. After their surgery, the gland will be biopsied and actual disease occurrence will be compared to the findings of the scans.

Dr. Cohen says previous studies indicate the new compound will be more accurate than current screening. “Ultrasound misses some prostate cancer and misdiagnoses some cases. This tracer may provide a more precise picture for us.”

Dr. Cohen says a big advantage with the new compound is that it can be seen on regular nuclear medicine cameras (like CTs and MRIs). It doesn’t require a special PET scanner—which current tests do—so it can be performed in more hospitals, with more patients.

Potential for targeted treatment

Dr. Cohen says the most exciting application of the new compound could actually be in fighting prostate cancer. “We can attach an agent to the compound to kill prostate cancer cells. The tracer could be injected into the body with the cancer-killing agent attached. It can then seek out and destroy prostate cancer cells.”  Dr. Cohen says researchers in Germany have initial indications that radioactive agents attached to the compound can be very successful in destroying prostate cancer cells when the compound binds to PSMA’s.

Dr. Cohen’s study is part of a large multi-centre trial. Johns Hopkins, the Cleveland Clinic, as well as Canadian sites like the Jewish General Hospital in Montreal and the Calgary Prostate Centre are other centres taking part.

“I think this compound is going to revolutionize the whole field. Nuclear medicine started out as a way to treat disease. But we haven’t had many successes and over time the field became more focussed on diagnosis of disease. This new agent could fulfill that original goal,” says Dr. Cohen.

Dr. Cohen is actively recruiting patients for the trial. He encourages men who are candidates for prostate gland removal to speak to their doctors about taking part. Participants will be asked to have one additional scan after an injection of the new tracer compound. Dr. Cohen hopes more men will be made aware of the trial and opt to take part.

“This agent is opening up significant advances in treatment and the only way to get it approved for use is to get trials done as quickly as possible.”

Learn more about the Prostate Cancer Trial.

 

Researchers

Philip Cohen

Related Articles

Discovery offers new insights to understand and treat prostate cancer

Welcoming the new M. H. Mohseni Institute of Urologic Sciences to VCHRI

Prostate Centre director’s new vision for urologic sciences research

Share:

  • Facebook
  • Linkedin
  • Twitter
  • Email

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Announcement

Celebrating the life and distinguished career of Dr. Marcel Dvorak

May 14, 2025
Type
Stories

More equitable representation needed in Parkinson’s research

May 9, 2025 parkinsons, patient engagement, women
Type
Stories

Gamified stroke recovery improves arm function

May 8, 2025 stroke, rehabilitation
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • X
  • YouTube

© 2025 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy